Impedimed Overview
Update this profile
Share Price
$0.04
(As of Thursday Closing)
Impedimed General Information
Description
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
Impedimed Stock Performance
(As of Thursday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$0.04
$0.04
$0.04 - $0.14
$74.9M
1.78B
1.97M
Impedimed Financials Summary
In Thousands, USD
TTM
31-Mar-2022
FY 2021
30-Jun-2021
FY 2020
30-Jun-2020
FY 2019
30-Jun-2019
EV
156,626
103,248
29,761
14,578
Revenue
6,227
3,814
2,930
EBITDA
(14,117)
(13,351)
(16,899)
Net Income
(15,437)
(14,319)
(17,248)
Total Assets
25,699
22,719
15,814
Total Debt
356
598
0
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Impedimed Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Impedimed‘s full profile, request access.
Request a free trial
Impedimed Patents
242
Total Documents
Applications and Grants
000
Total Patents
Families
15
Granted
4
Pending
000
Expiring
in next 12 mo
Impedimed Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
AU-2019348188-A1
Evaluating impedance measurements
Pending
27-Sep-2018
0000000000
EP-3856024-A1
Evaluating impedance measurements
Pending
27-Sep-2018
0000000000
JP-2020523162-A
Index determination
Pending
14-Jun-2017
0000000000
EP-3634226-A1
Indicator determination
Pending
14-Jun-2017
0000000000
AU-2018286480-A1
Indicator determination
Pending
14-Jun-2017
A61B5/0537
To view Impedimed’s complete patent history, request access »
Impedimed Executive Team (5)
Update this profile
Name
Title
Board Seat
Contact Info
Richard Carreon
President, Managing Director & Chief Executive Officer
Phil Auckland
Chief Financial Officer & Chief Operating Officer
Morten Vigeland
Chief Financial Officer
Chris Bulger
Director, Business Development
You’re viewing 4 of 5 executive team members. Get the full list »
Impedimed Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial